Angina Pectoris and Myocardial Ischemia in the Absence of Obstructive Coronary Artery Disease: Practical Considerations for Diagnostic Tests  by Radico, Francesco et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 5 , 2 0 1 4
ª 2 0 1 4 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 4 . 0 1 . 1 5 7STATE-OF-THE-ART PAPERAngina Pectoris and Myocardial Ischemia in the
Absence of Obstructive Coronary Artery Disease:
Practical Considerations for Diagnostic Tests
Francesco Radico, MD, Vincenzo Cicchitti, MD, Marco Zimarino, MD, PHD,
Raffaele De Caterina, MD, PHD
Chieti, ItalyJACC:CARDIOVASCULARINTERVENTIONSCME
This article has been selected as this issue’s CME activity,
available online at http://interventions.onlinejacc.org/
by selecting the CME tab on the top navigation bar.
Accreditation and Designation Statement
The American College of Cardiology Foundation (ACCF)
is accredited by the Accreditation Council for Continuing
Medical Education (ACCME) to provide continuing
medical education for physicians.
The ACCF designates this Journal-based CME activity
for a maximum of 1 AMA PRA Category 1 Credit(s).
Physicians should only claim credit commensurate with
the extent of their participation in the activity.
Method of Participation and
Receipt of CME Certiﬁcate
To obtain credit for this CME activity, you must:
1. Be an ACC member or JACC: Cardiovascular Interventions
subscriber.
2. Carefully read the CME-designated article available
online and in this issue of the journal.
3. Answer the post-test questions. At least 2 out of the 3
questions provided must be answered correctly to obtain
CME credit.
4. Complete a brief evaluation.
5. Claim your CME credit and receive your certiﬁcate
electronically by following the instructions given at the
conclusion of the activity.
CME Objective for This Article: At the completion of
this article, the learner should be able to: 1) diagram the
diagnostic algorithm in patients presenting with angina
and signs of myocardial ischemia; 2) differentiate between
vasospastic angina, microvascular angina and cardiac syn-
drome X; and 3) summarize the available diagnostic tests
in the evaluation of a patient with angina and the absence
of obstructive coronary artery disease.
CME Editor Disclosure: JACC: Cardiovascular Interventions
CME Editor Habib Samady, MB, ChB, FACC, has
research grants from the Wallace H. Coulter Foundation,
Volcano Corp., St. Jude Medical, Forrest Pharmaceuticals
Inc., and Pﬁzer Inc.
Author Disclosure: The authors have reported that they
have no relationships relevant to the contents of this paper
to disclose.
Medium of Participation: Print (article only); online
(article and quiz).
CME Term of Approval:
Issue Date: May 2014
Expiration Date: April 30, 2015
From the Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University, Chieti, Italy. The authors have
reported that they have no relationships relevant to the contents of this paper to disclose.
Manuscript received September 19, 2013; revised manuscript received January 3, 2014, accepted January 16, 2014.
Radico et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 5 , 2 0 1 4
Tests for Angina Without Obstructive CAD M A Y 2 0 1 4 : 4 5 3 – 6 3
454Angina Pectoris and Myocardial Ischemia in the Absence of Obstructive
Coronary Artery Disease: Practical Considerations for Diagnostic TestsAngina andmyocardial ischemia without obstructive coronary artery disease are common clinical ﬁndings, often neglected for the
assumption of a good prognosis. Most often, such patients are neither further investigated nor offered speciﬁc treatment beyond
reassurance. However, the absenceof signiﬁcant coronary stenoses onangiographydoesnot necessarily imply a “healthy” coronary
tree. In such cases, myocardial ischemia may result from different types of functional disease involving the epicardial coronary
arteries, the coronary microcirculation, or both; an accurate assessment of these components should be systematically performed
after exclusion of organic epicardial disease because a correct diagnosis has relevant prognostic and therapeutic implications. Here
we discuss the basic principles of diagnostic tests in this setting and propose a diagnostic sequence of reasonable practical
implementation that may help identify patients at risk of future cardiac events. (J Am Coll Cardiol Intv 2014;7:453–63)ª 2014 by
the American College of Cardiology FoundationMyocardial ischemia always results from an imbalance
between myocardial metabolic demand and coronary
blood supply. In a stable clinical situation, this is mainly
related to epicardial atherosclerotic coronary artery dis-
ease (CAD), which hinders the dynamic adjustment of
coronary blood ﬂow (CBF) to increased myocardial
metabolic demand (1). However, the angiographic evi-
dence of a “normal” or mildly diseased epicardial coro-
nary tree, usually deﬁned as the absence of a luminal
diameter reduction of 50% (or >70% of the luminal area
reduction) (2), is a common ﬁnding, as it is documented in
w20% to 30% of patients undergoing coronary angiography
(3–5), with a higher prevalence (almost 50%) in women (5).
This condition is usually deﬁned as angina with “normal”
coronary arteries, or, more correctly, angina in the absence of
obstructive CAD. Here myocardial ischemia may result from
different types of functional disease involving the epicardial
coronary arteries, the coronarymicrocirculation, or both (6). At
centers investigating coronary vasomotion after diagnostic
angiography, abnormal epicardial and/or microvascular coro-
nary dysfunction can be detected in a large portion (up to 60%)
of patients with no or minimal CAD (6). The large variability
of this ﬁnding depends on the selection criteria for coronary
angiography, the on-site availability of a program to investigate
coronary vasomotion, and the procedural protocols speciﬁcally
elected and adopted.
Patients with stable angina in the absence of obstructive
CAD are often inappropriately reassured and even dis-
charged without further investigation or treatment. How-
ever, they have an increased mortality, a higher
rehospitalization rate, and a worse quality of life compared
with healthy subjects (5,7). Therefore, there is a true need
for a precise diagnostic algorithm that may help identify and
treat such patients who appear to be at risk of future cardiac
events.Why Pursue a Correct Diagnosis?
Angina in the absence of obstructive CAD has been asso-
ciated with a 1.5-fold higher mortality rate compared with a
reference population without any evidence of myocardial
ischemia (5). In addition, quality of life is signiﬁcantly
affected because >40% of these patients are rehospitalized
for chest pain, and 30% undergo repeat coronary angiog-
raphy (8). This obviously means high healthcare costs,
similar to those of obstructive CAD.
The prognosis of angina without obstructive CAD is
indeed dependent on the underlying pathophysiological
mechanisms. Apart from the rare occurrence of organic
causes of myocardial ischemia in the absence of signiﬁcant
CAD (Table 1), ischemic heart disease (IHD) in such cases
may result from: 1) a functional disorder (spasm) of the
epicardial coronary arteries (paradigmatically with transient
ST-segment elevation, so-called Prinzmetal angina, but
often with ST-segment depression and/or T-wave changes),
whereby an atypical form, termed Prinzmetal X, has been
reported as occurring during physical exercise, thus pre-
senting as effort angina (9); or 2) a microcirculatory abnor-
mality in the absence of structural or functional epicardial
CAD (the concept of cardiac syndrome X was historically
introduced). In such cases, an isolated involvement of the
coronary microcirculation can be postulated: both structural
and functional abnormalities have been described, with either
endothelial dysfunction and reduced bioavailability of the
vasodilator nitric oxide or microcirculatory impairment of
endothelium-independent vasodilation (10). This condi-
tion, today referred to microvascular angina (10), may be
idiopathic or secondary to systemic or myocardial diseases.
The term cardiac syndrome X should now be abandoned.
In the few cases in which the pathogenesis of the syndrome
remains unknown and microvascular impairment is not
Abbreviations
and Acronyms
CAD = coronary artery
disease
CBF = coronary blood ﬂow
CFR = coronary ﬂow reserve
FFR = fractional ﬂow reserve
IHD = ischemic heart disease
IMR = index of
microcirculatory resistance
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455identiﬁed, neurological mechanisms also involving changes in
pain perception can be hypothesized (11), and the diagnosis of
“true” cardiac syndrome X may still be considered reasonable.
Thus, the 3 terms, angina without obstructive CAD, micro-
vascular angina, and “true” syndrome X (Table 2), should not
be used interchangeably, because such conditions have a
different prognostic relevance and they require an individual-
ized therapeutic strategy. In Table 2, we provide a list of
deﬁnitions, proposed but not universally accepted, to clarify
terms and highlight the differences among the various path-
ological entities.
Microvascular angina accounts for at least one-third of the
cases of angina in the absence of obstructive CAD (6); both
endothelium-dependent (12) and endothelium-independent
(7,13) coronary microvascular dysfunction are predictive
of a worse outcome. Patients with coronary endothelial
dysfunction showed a 20% higher rate of cardiovascular
events (death, acute coronary syndromes, stroke, and need
for revascularization) at 46-month follow-up (12). Among
patients with intermediate lesions, microvascular dysfunc-
tion was associated with a 3.3-fold increase in the risk of
cardiac death at 12 years (36.9%) compared with subjects
having a normal endothelial function (7).
Patients reporting vasospastic angina have a 25% higher
probability of experiencing myocardial infarction or cardiac
death at 3-year follow-up (14). A scoring system for pre-
dicting adverse cardiac events was recently developed, based
on a history of out-of-hospital cardiac arrest (4 points),
smoking, angina at rest alone, the presence of organic coro-
nary stenoses, multivessel spasm (2 points each), ST-segment
elevation during angina, and the use of b-blockers (1 point
each). Patients in the low (<3), intermediate (3 to 5), and
high (>5) score risk strata had a statistically signiﬁcant
(p < 0.001) different incidence of adverse events at
32 months (2.5%, 7.0%, and 13.0%, respectively) (15).
From a therapeutic standpoint, calcium channel blockers
are widely used in patients with vasospastic angina, and
their beneﬁts are mainly attributable to their capacity to
prevent arterial vasoconstriction by inducing relaxation of
vascular smooth muscle cells (16). Nitrates are also effective
in preventing coronary vasospasm (17). Today b-blockers
represent a cornerstone of the pharmacological therapy of
IHD, but their role is controversial in patients with vaso-
spastic angina; once believed to be detrimental (18), third-
generation b-blockers were later credited with vasorelaxing
properties through adenosine triphosphate efﬂux-mediated
stimulation of nitric oxide from endothelial cells (19). In
patients with microvascular angina, atenolol was proven
even more effective than amlodipine and nitrates in sup-
pressing chest pain episodes (20). Moreover, b-blockers still
remain the reference standard for treating patients with a
myocardial bridge, mainly due to their negative chrono-
tropic effect. Statins and angiotensin-converting enzyme
inhibitors seem to be able to improve exercise capacity inpatients with cardiac syndrome X, mainly by improving
endothelial function and reducing oxidative stress (21).
However, the evidence of their efﬁcacy is poor and often
based on surrogate endpoints and indirect indicators of
myocardial ischemia.
In patients with microvascular angina, symptoms often
persist despite full classic anti-ischemic therapy. A potential
beneﬁt may derive from newer antianginal drugs: compared
with placebo, both ranolazine and ivabradine improved
symptoms in 46 patients, with ranolazine signiﬁcantly more
effective in increasing the ischemic threshold on the exercise
stress test (22). However, no direct beneﬁt of these drugs on
coronary microvascular function was found (22). In another
study carried out in women without obstructive CAD,
ranolazine versus placebo improved angina and exerted a
favorable effect on myocardial ischemia more evidently in a
subgroup of women with altered compared with women
with a normal coronary ﬂow reserve (CFR) (23).
Diagnostic AssessmentBecause the pathophysiology of
angina without obstructive CAD
has relevant prognostic and
therapeutic implications, the use
of functional testing should be
advocated. In this regard, we
disagree with the recently issued
guidelines of the European So-
ciety of Cardiology on stable
CAD in which the authors
conﬁne adenosine and acetyl-
choline tests to a weak class of
recommendation (IIb) (2).
Epicardial vasoreactivity. In patients with angina in the
absence of obstructive CAD on angiography, the diagnostic
algorithm should ﬁrst logically exclude organic non-
atherosclerotic causes of epicardial CAD (Table 1) and sig-
niﬁcant lesions underestimated by angiography. Intermediate
stenoses (50% to 70% diameter reduction), especially when
occurring along the same vessel, are worthy of a functional
evaluation, now feasible with pressure guidewires through the
assessment of the fractional ﬂow reserve (FFR) (24). An
important consideration in this regard is that increased
vasoconstrictive tone or the presence of a diffuse and
circumferential disease along the vessel may both lead to an
underestimation of the reference vessel diameter and there-
fore of the real extent of a coronary stenosis. In such cases, the
intracoronary injection of nitrates fully and selectively dilates
normal vessels, thus differentiating between normal and
diseased segments (17). From this assumption, a practical
problem arises because pretreatment with intracoronary
nitrates may interfere with subsequent vasoreactivity tests.
The vasodilatory effect of nitroglycerin peaks at 3 to 5 min
Table 1. Organic Nonatherosclerotic Causes of Epicardial Coronary
Artery Disease
Mechanism Involved
Coronary aneurysms Slowdown of coronary blood ﬂow and thromboembolic
phenomena
Myocardial bridging Phasic ab extrinseco constriction of coronary arteries
during the systolic phase of the cardiac cycle
Coronary anomalies Extrinsic compression of an epicardial vessel (e.g.,
anomalous left main artery running between the
aorta and the pulmonary trunk during exercise)
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456after intracoronary injection and lasts forw12 min in normal
segments and 15 min in stenotic segments (25). Therefore,
intracoronary injection of nitrates during diagnostic angi-
ography should be reserved only to those cases in which
there is real doubt about the signiﬁcance of the stenosis. In
such cases, a functional evaluation of the coronary artery
system should be delayed by at least 15 min.
After excluding signiﬁcant organic CAD by angiography,
functional causes involving the epicardial coronary arteries
should be investigated. Vasospasmmay occur during daily lifeTable 2. Proposed Deﬁnitions
Angina without obstructive CAD
Typical exercise-induced angina
Documented stress-induced myocardial ischemia
Absence of obstructive atherosclerotic CAD*
Cardiac syndrome X (reported here only for historical reasons)
Typical exercise-induced angina
Documented stress-induced myocardial ischemia
Absence of obstructive atherosclerotic CAD*
Absence of organic nonatherosclerotic causes of epicardial CADy
Absence of vasospastic angina (no epicardial vasospasm at ergonovine or
acetylcholine test)
Microvascular angina
Typical exercise-induced angina
Documented stress-induced myocardial ischemia
Absence of obstructive atherosclerotic CAD*
Absence of organic nonatherosclerotic causes of epicardial CADy
Absence of vasospastic angina (no epicardial vasospasm at ergonovine or
acetylcholine test)
Active demonstration of coronary microcirculation dysfunction (positive
acetylcholine and/or adenosine test results)
True cardiac syndrome X
Typical exercise-induced angina
Documented stress-induced myocardial ischemia
Absence of obstructive atherosclerotic CAD*
Absence of organic nonatherosclerotic causes of epicardial CADy
Absence of vasospastic angina (no epicardial vasospasm at ergonovine or
acetylcholine tests)
No demonstration of coronary microcirculation dysfunction (negative
acetylcholine and adenosine test results)
*Obstructive atherosclerotic CAD is deﬁned in the presence of luminal diameter reduction of
50% (or >70% of luminal area reduction) (2). yCoronary aneurysms, myocardial bridging,
coronary anomalies (as in Table 1).
CAD ¼ coronary artery disease.in response to various stimuli (smoking, cold, cocaine use,
metabolic disturbances, physical or mental stress), and
diagnostic protocols combining some of these several stimuli
are occasionally adopted. The cold pressor test and/or the
hyperventilation test, alone or in combination, are relatively
safe vasoconstrictive stimuli and are usually coupled with
noninvasive diagnostic tests. Compared with the sole in-
duction/noninduction of angina or ST-segment changes on
electrocardiography, echocardiography has better sensitivity
and better diagnostic accuracy for coronary vasospasm
(60% vs. 91%, respectively) and also permits the identiﬁca-
tion of the speciﬁc myocardial segment(s) undergoing tran-
sient ischemia, therefore allowing inferences regarding the
culprit coronary artery (26) (Table 3). However, because
nonpharmacological spasm-provoking protocols still have an
overall poor sensitivity, pharmacological tests are now more
widely accepted. Ergonovine (otherwise called ergometrine)
is an ergot alkaloid acting as a serotonin agonist that induces
vasospasm in patients affected by variant angina via a me-
chanismmediated by the hypersensitivity of the 1D serotonin
receptor subtype in vascular smooth muscle cells. Methyl-
ergonovine (methylergometrine) is a synthetic analog of
ergonovine, apparently acting not solely on vascular smooth
muscle cells but also on the endothelial serotonin receptors,
thus inducing a coronary vasospasm that is at least in part
caused by endothelial dysfunction (27). The ﬁrst provocation
tests with ergonovine during coronary angiography were
performed in the late 1970s (28) by intravenous injection of
either a single bolus of methylergonovine maleate or repeated
boluses at increasing doses. The diagnostic detection of
vasospasm was at that time obtained either indirectly with
noninvasive protocols by electrocardiography (29) or echo-
cardiography (30) or directly by invasive angiography (28).
However, dangerous complications, such as life-threatening
arrhythmias, acute myocardial infarction, severe hypotension,
and even death were reported after the intravenous admin-
istration of ergonovine, which can trigger refractory and
multivessel spasms, in some cases without the possibility of a
prompt reversal by intracoronary nitrates (31). Noninvasive
ergonovine protocols were thus discouraged, and provocative
tests with intracoronary administration were instead advo-
cated (32) (Table 3). The direct intracoronary route appears
to be safer and with a similar or even a greater degree of
coronary constrictive responses of spasm-prone coronary
segments compared with intravenous administration (33).
Thus, intracoronary ergonovine is now recommended by the
European guidelines as a valuable alternative to intracoronary
acetylcholine to assess epicardial coronary vasospasm (2).
Acetylcholine produces coronary vasodilation in the
presence of a healthy endothelium (34) while causing a
paradoxical vasoconstriction when endothelial dysfunction is
present (35) (Fig. 1, Table 3). The diagnostic accuracy of
acetylcholine administration is comparable to that of intra-
coronary ergonovine (36). Moreover, acetylcholine has the
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457advantage of also allowing the identiﬁcation of a coronary
microvascular endothelial dysfunction (as discussed later).
At least 2 considerations are, however, still opportune
about acetylcholine and ergonovine intracoronary tests: ﬁrst,
their safety still remains a major concern, although it seems
to be acceptable because diffuse coronary spasm can be easily
reversed by intracoronary nitrate injection. Indeed, exces-
sively aggressive protocols may be responsible for the higher
occurrence of major arrhythmias reported with acetylcholine
(9.3%) compared with ergonovine (3.2%, p < 0.001) (37).
With slower infusion rates of acetylcholine, only transient
atrioventricular blocks, spontaneously resolved in a few
seconds due to the short acetylcholine half-life, have been
reported (6). Second, there is no universal consensus on
the deﬁnition of coronary spasm because visually assessed
lumen diameter reductions ranging from 75% to 90%
compared with a reference vessel diameter after nitroglycerin
injection have been described as spasm (6,37). Indeed, the
response to vasoconstrictive stimuli can vary. At 1 end of
the spectrum is the physiological diffuse and mild vaso-
constriction in response to ergonovine observed in normal
epicardial coronary arteries; at the other extreme, there is the
severe segmental constriction leading to total artery occlu-
sion, as typically observed in patients with variant angina.
Intermediate forms of coronary constriction, reducing
local diameter by at least 50%, are still of equivocal inter-
pretation, but seem to indicate the potential for the deve-
lopment of occlusive spasm in response to stronger
stimulations (38).
The coronary microcirculation: invasive assessment. Once
epicardial coronary artery spasm is excluded, involvement of
the coronary microcirculation can be hypothesized and
should then be actively investigated. The direct assessment of
microcirculatory dysfunction is, however, challenging for
several reasons. The spatial resolution of coronary angiog-
raphy is relatively poor (0.5 mm), thus hampering a detailed
evaluation of the small resistance vessels (0.1 to 0.3 mm in
diameter); techniques required for evaluation of the micro-
circulation (e.g., acetylcholine and adenosine tests) are
considered complex, invasive, time-consuming, or expensive
or are still not widely available (e.g., cardiac magnetic reso-
nance imaging).
Coronary microvascular disease may in turn be related to
endothelium-dependent or endothelium-independent dys-
function, this latter due to an abnormal response of resis-
tance vessels to direct vasodilatory stimuli. Accordingly, both
the endothelium-dependent and the endothelium-indepen-
dent functions should be assessed.
ASSESSMENT OF ENDOTHELIUM-DEPENDENT CFR. Intracoro-
nary acetylcholine administration during coronary angiog-
raphy is now considered the reference standard for the
evaluation of coronary endothelium–dependent vasodilation
(2). After intracoronary injection of acetylcholine, epicardialor microvascular spasms can be detected according to
angiographic, electrocardiographic, and clinical ﬁndings (6)
(Table 3).
ASSESSMENT OF ENDOTHELIUM-INDEPENDENT VASODILATION.
In physiological conditions, CBF increases by at least 3 to 4
times in response to increased myocardial oxygen re-
quirements. The ability of CBF to adapt to match the
metabolic demand is deﬁned as CFR and is measured as
the ratio of the maximal ﬂow after a hyperemic stimulus
to the baseline resting blood ﬂow: CFR ¼ [hyperemic
(V/Tmn)]/[rest (V/Tmn)], where V indicates the vascular
volume between the injection site and the measuring site
of the indicator, and Tmn the mean transit time of the
indicator to travel from the injection site to the distal sensor
(1). Adenosine is an endogenous purine nucleoside physi-
ologically released from ischemic myocardial cells during
ischemia. Adenosine causes vascular smooth muscle cell
relaxation (Fig. 1) and is used to cause a massive direct
endothelium-independent coronary microvascular vasodi-
lation (Table 3). In addition, nicorandil has been proposed
as a novel hyperemic agent. Nicorandil is a nicotinamide
ester that releases nitric oxide in the same fashion as
organic nitrates and opens adenosine triphosphate–sensi-
tive potassium channels, thereby causing dilation of both
coronary epicardial arteries and resistance arterioles. In a
recent study, the hyperemic efﬁcacy of an intracoronary
bolus injection of nicorandil 2 mg was not inferior to the
intravenous infusion of adenosine to obtain the FFR and
the index of microcirculatory resistance (IMR) (see the
following), but also showed a better safety proﬁle (39)
(Table 3).
CFR can be assessed during coronary angiography by
Doppler or thermistor/pressure sensor guidewires. The latter
are now preferred because they are more robust thanDoppler-
derived CFR measurements mainly due to the difﬁculties of
Doppler velocity measurements in differentiating ﬂow ve-
locity signals from vascular wall motion artifacts and for the
capacity offered by pressure systems also to measure FFR (40)
(Table 3). However, CFR assesses the ﬂow of the entire
coronary system, and its reductions are sensitive to both
epicardial CAD andmicrocirculatory disease. For this reason,
CFR is a valuable index of microcirculatory dysfunction only
after excluding the presence of signiﬁcant epicardial CAD.
IMR ¼ Pd/Tmn1, where Pd is the distal coronary
pressure, has been proposed to overcome the limits of CFR
(41): both Pd and Tmn are obtained after the intracoronary
injection of 3 ml of room-temperature saline solution and
measured with a pressure wire under full adenosine vasodi-
lation, thus potentially eliminating the variability of resting
vascular tone and possible epicardial stenoses. Compared
with CFR, IMR provides a more reproducible assessment of
the microcirculation, which is independent of hemodynamic
perturbations (42). With a single pressure wire, both FFR
Table 3. Protocols for Diagnostic Tests in the Evaluation of a Patient With Angina and Absence of Obstructive CAD
Test Protocol Monitoring Interpretation Ref. #
Hyperventilation and
cold-pressor stress
echocardiography
Hyperventilation for 6 min (30
respiration/min); then right-hand
immersion in ice water for 2 min.
ECG and/or echocardiographic
continuous monitoring during the
stress time and for the next 15 min.
Positive for coronary vasospasm: ECG
(ST-segment elevation 1 mm) or
echocardiographic ischemic changes
(new wall motion abnormalities).
(26)
Intracoronary ergonovine Injection of 20–60 mg ergonovine in
saline solution into the LCA over
2–5 min; in case of negative result after
5 min/ 20–60 mg over 2–5 min into
the RCA. 2.5–5.0 mg of ISDN or 0.2 mg
GTN when spasm occurs or at the end
of the test.
Coronary angiography:
2 min after ergonovine injection
If ischemic changes on the
electrocardiogram or chest pain.
At the end of the test when the
coronary artery is maximally dilated
(after ISDN or GTN into each coronary
artery).
Arterial blood pressure and
electrocardiogram continuously
monitored.
Positive for epicardial coronary spasm:
>90% luminal narrowing compared
with the maximal dilation state with
chest pain and/or ECG ischemic
changes.
(37)
Acetylcholine test Incremental doses of acetylcholine
administered over 3 min each into the
LCA (2, 20, 100, and 200 mg). In case of
negative result after 5 min/ 80 mg
over 3 min into the RCA. 2.5–5.0 mg of
ISDN or 0.2 mg of GTN when spasm
occurs or at the end of the test.
Coronary angiography:
After each acetylcholine injection;
In the event of ischemic changes on
the electrocardiogram or chest pain;
At the end of the test when the
coronary artery is maximally dilated
(after ISDN or GTN into each coronary
artery). Arterial blood pressure and
electrocardiogram continuously
monitored.
Positive for epicardial coronary spasm:
75% focal or diffuse coronary artery
diameter reduction (compared with
the relaxed state after intracoronary
ISDN or GTN).
Reproduction of angina
Ischemic ECG changes
Positive for microvascular spasm:
Absence of epicardial spasm (<75%
diameter reduction);
Reproduction of angina;
Ischemic ECG changes
(ST-segment depression or ST-segment
elevation of 0.1 mV or T-wave peaking
in at least 2 contiguous leads).
(6)
Adenosine test Intracoronary bolus injections of 18 mg
adenosine into the LCA (or 12 mg in the
RCA) diluted in 2 ml of normal saline
solution and followed by a 5-ml saline
solution ﬂush.
At least 3 injections are required to
ensure a stable average peak CFV.
Stable hyperemia may also be
induced by intravenous adenosine
(140 mg/kg/min via a central vein).
Sensor-tipped guidewire (equipped with
either a Doppler probe or thermistor/
pressure sensor) advanced through the
diagnostic catheter in a stenosis-free
area of the epicardial artery.
1. Obtain average baseline CFV
2. Obtain a stable average peak CFV
(after 3 adenosine injections over 2
cardiac cycles with a 2-mm sample
volume at a location w5 mm distal to
the tip of the guidewire).
3. Calculate CFR: ratio of average peak
CFV to average baseline CFV.
Positive for coronary microvascular
endothelium-independent
dysfunction:
CFR <2.5 in the absence of signiﬁcant
epicardial coronary artery stenosis
(13,43,52)
Intracoronary nicorandil Intracoronary bolus injection of 2 mg
nicorandil
As a hyperemic endothelium-
independent agent, nicorandil allows
measurements of:
FFR (mean distal coronary pressure
divided by mean aortic pressure at
maximal hyperemia).
IMR (distal coronary pressure at
maximal hyperemia multiplied by the
hyperemic mean transit time)
CFR: ratio of average peak CFV to
average baseline CFV.
Positive for coronary microvascular
endothelium-independent
dysfunction:
CFR <2.5 (or an impaired IMR) in the
absence of signiﬁcant epicardial
coronary artery stenosis (FFR >0.80).
(39)
Transthoracic color Doppler
echocardiography
Intravenous administration of adenosine
(0.14 mg/kg/min for 90 s).
Transthoracic echocardiography
performed in the left lateral decubitus
at the cardiac apex to image the distal
anteroseptal; then distal left anterior
descending artery is visualized by color
Doppler and pulsed Doppler is used to
measure CFV and CFR (ratio of average
peak CFV after adenosine to average
baseline CFV).
Positive for coronary microvascular
endothelium-independent
dysfunction: CFR <2.0 in the absence
of signiﬁcant epicardial coronary artery
stenosis
(44,45)
Continued on the next page
Radico et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 5 , 2 0 1 4
Tests for Angina Without Obstructive CAD M A Y 2 0 1 4 : 4 5 3 – 6 3
458
Table 3. Continued
Test Protocol Monitoring Interpretation Ref. #
Myocardial contrast
echocardiography
Intravenous administration of an
ultrasound contrast agent
(microbubbles of sulfur hexaﬂuoride
surrounded by a phospholipid shell)
and adenosine (0.14 mg/kg/min
for 90 s).
Contrast images are acquired in an apical
4-chamber view, and myocardial
opaciﬁcation is quantiﬁed in the
posterior interventricular septum and
lateral left ventricular by a speciﬁc
software.
CFR assessment: comparison of contrast
intensity at rest and at peak adenosine.
Positive for coronary microvascular
endothelium-independent
dysfunction: CFR <2.0 in the absence
of signiﬁcant epicardial coronary artery
stenosis.
(46)
Adenosine stress perfusion
cardiac magnetic
resonance
Intravenous administration of gadolinium
contrast and adenosine (0.14 mg/kg/
min for 3 min).
Perfusion cardiac magnetic resonance
images: adenosine gadolinium ﬁrst-
pass imaging for assessment of stress
perfusion repeated after 15 min for
assessment of rest perfusion.
Positive for coronary microvascular
dysfunction:
Reduced or even absent gadolinium
enhancement in the corresponding
subendocardial layer.
(47)
Positron emission
tomography perfusion
imaging
Intravenous administration of a speciﬁc
cardiovascular radioisotopic tracer
(13NH3, H2
15O, and 82Rb) and
adenosine (or dipyridamole).
MBF assessment is achieved by the
quantiﬁcation of the myocardial
radioisotopic-tracer uptake.
CFR assessment: ratio of MBF in
hyperemic conditions and at rest.
Positive for coronary microvascular
endothelium-independent
dysfunction: CFR <2.5 in the absence
of signiﬁcant epicardial coronary artery
stenosis.
(48)
Multislice detector
computed tomography
Intravenous administration of iodinated
contrast and adenosine (0.14 mg/kg/
min for 5 min).
Images are analyzed by measuring the
attenuation changes over time in basal
and hyperemic conditions and plotting
time-attenuation curves.
CFR: ratio of area under the curve for the
hyperemic territory to the remote
territory.
Positive for coronary microvascular
endothelium-independent
dysfunction: CFR <2.5 in the absence
of signiﬁcant epicardial coronary artery
stenosis.
(50)
CFR ¼ coronary ﬂow reserve; CFV ¼ coronary ﬂow velocity; ECG ¼ electrocardiographic; FFR ¼ fractional ﬂow reserve; GTN ¼ glyceryl trinitrate, nitroglycerin; IMR ¼ index of microcirculatory resistance;
ISDN ¼ isosorbide dinitrate; LCA ¼ left coronary artery; MBF ¼ myocardial blood ﬂow; RCA ¼ right coronary artery.
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459and IMR can be measured, providing a comprehensive and
speciﬁc assessment of both epicardial and microvascular
coronary physiology. Despite these convincing pathophysi-
ological principles and promising preliminary clinical evi-
dence, data on patients with microvascular angina are scant,
and there are no established cut-off values for IMR. Re-
cently, an upper limit of normal set at 29 U, as the highest
interquartile range in a population of patients with inter-
mediate coronary artery lesions, was identiﬁed (43). There-
fore, its assessment cannot be currently recommended as a
reference standard for the assessment of coronary micro-
vascular function. Moreover, an impaired CFR may result
not only from increased microvascular resistances, but also
from an abnormally increased basal ﬂow velocity, which
could be related to altered coronary autoregulation. The
latter is proposed as a new pathophysiological mechanism
explaining altered CFR in patients with angina without
obstructive CAD (7).
The coronary microcirculation: noninvasive assessment.
To overcome the obvious limitations of invasive meth-
ods to assess coronary microvascular function, several
noninvasive techniques are being developed and validated
(Table 3).
Pulsed-wave Doppler recording of CBF in the left ante-
rior descending artery (44), obtained by transthoracic
echocardiography before and after adenosine infusion, is the
most reliable noninvasive method to assess CFR (45) and isnow suggested by the new European guidelines with the
same class of recommendation (IIb) as the intracoronary
adenosine test during coronary angiography (2). Other
studies have also proposed using myocardial contrast echo-
cardiography to detect perfusion defects and to estimate
CFR (46).
Perfusion imaging by gadolinium-enhanced stress cardiac
magnetic resonance is another promising technique for the
identiﬁcation of subendocardial perfusion defects induced by
adenosine through a coronary steal phenomenon in
myocardial areas supplied by a dysfunctional microcircula-
tion (47).
Perfusion imaging with positron emission tomography is
also considered an accurate test for the assessment of
myocardial blood ﬂow achieved by quantifying the uptake of
a speciﬁc cardiovascular radioisotopic tracer (48).
Last, multislice detector computed tomography with an
iodinated contrast is capable of providing an estimate of
myocardial blood ﬂow and CFR by measuring the attenu-
ation changes over time in basal and hyperemic conditions
and plotting time-attenuation curves (49). Recently intro-
duced 320-row scanners allow the acquisition of a full car-
diac tomographic dataset within a single heart beat, reducing
iodine contrast volumes and radiation doses (50).
Unfortunately, these noninvasive methods are all, albeit to
a variable degree, expensive and available only in few
research centers. Moreover, they still lack sensitivity and
Figure 1. Acetylcholine and Adenosine Coronary Vascular Effects
Acetylcholine (ACH) has dual antithetical effects on the coronary arteries. By binding to muscarinic 3 (M3) receptors on the surface of vascular smooth muscle cells, it
elicits (arrow andD) an intracellular release of calcium ions (Ca2þ), leading to vasoconstriction, whereas endothelial M3 receptor–mediated Ca2þ release activates the
endothelial nitric oxide (NO) synthase (eNOS, NOS III) through a calmodulin-dependent pathway. NO is then released and, in vascular smooth muscle cells, activates
soluble guanylate-cyclase (sGC), which converts (curved arrow) guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). The subsequent acti-
vation of GMP-dependent protein kinase (PKG) induces a cascade of intracellular events with the ﬁnal effect of decreasing (arrow and L) intracellular Ca2þ con-
centrations, leading to vasodilation. Adenosine (ADE) binds to its receptors (A2a) on the surface of vascular smooth muscle cells, activating adenylate cyclase (AC) and
leading to an increase in cyclic adenosine monophosphate (cAMP) concentration and cAMP-dependent protein kinase (PKA) activation. The latter results in potassium
(Kþ) channel opening, resulting in a hyperpolarization of vascular smooth muscle cells, inhibits the entry of Ca2þ and also activates inducible NOS (iNOS) (NOS II), thus
producing vasodilation. ATP ¼ adenosine triphosphate.
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460speciﬁcity and are often unable to differentiate between
epicardial and microvascular abnormalities. There is also a
lack of cross-center validation, which is at the moment a
strong source of concern. In conclusion, at present, they only
represent promising alternatives to currently available inva-
sive techniques.
Proposal of a Comprehensive Diagnostic Algorithm
Here we propose a diagnostic algorithm (Fig. 2) for patients
with typical angina and documentation of myocardial
ischemia in the absence of obstructive CAD. In an effort to
obtain a good compromise between theoretically ideal tests
and practically feasible ones, this scheme should be seen as a
work-in-progress and may be reﬁned when better techniques
or more complete evaluations of current techniques become
available.
First of all, every patient undergoing coronary angiog-
raphy for effort angina and unequivocal signs of exercise-
induced myocardial ischemia should discontinue at least
24 h before the examination any cardiovascular medication
able to affect coronary vasomotor responses (6) so as not topreclude a possible functional evaluation of the coronary
circulation. Likewise, routine pretreatment with intra-
coronary nitroglycerin after coronary cannulation should be
avoided. It would be also preferable to perform coronary
angiography in the morning to take advantage of the low
threshold for vasospasm described in the circadian rhythm of
vasomotor responses.
When a subcritical or intermediate lesion is documented,
FFR should be considered to exclude its functional rele-
vance (nonpathological FFR value 0.80), especially in the
presence of a series of moderate lesions in the same vessel,
which might produce additive effects (24). Some concern
was recently expressed about the sensitivity of this tech-
nique due to a differential reduction of pressure induced by
adenosine in coronary and systemic vascular beds (51) and
in cases of irreversibly increased microcirculatory resistance
(as detected by increased IMR) (43). Nevertheless, the FFR
remains the reference method for assessing lesion functional
relevance.
In the absence of signiﬁcant atherosclerotic lesions or
any other nonatherosclerotic epicardial coronary disease
(Table 1), the acetylcholine test should be performed.
Figure 2. Diagnostic Algorithm in Patients’ Typical Effort Angina and Signs of Myocardial Ischemia
Coronary angiography should be performed in the morning to take advantage of the lower circadian threshold for vasospasm in these hours of the day. Calcium
channel blockers, b-blockers, and long-acting nitrates should be discontinued at least 24 h before coronary angiography. A functional evaluation of lesion severity by
fractional ﬂow reserve (FFR) (normal values 0.80) is recommended in the presence of a moderate disease, but it might be performed as a conﬁrmation of angio-
graphic ﬁndings also in cases of a mild or severe disease. In the absence of a signiﬁcant organic epicardial disease due to either atherosclerotic (signiﬁcant
atherosclerotic coronary artery disease [CAD]) or to other nonatherosclerotic causes (anomalous coronary origin, myocardial bridge, or coronary aneurysm) (non-
atherosclerotic CAD), the acetylcholine test can identify the presence of vasospastic or microvascular angina. When the acetylcholine test result is negative, adenosine
testing can explore the presence of a microvascular angina, based on the ﬁnding of an impaired coronary ﬂow reserve (CFR) (<2.5). In patients with no CAD and
normal acetylcholine and adenosine test results, a potential myocardial ischemia due to unknown and/or undetectable causes can be hypothesized if the probability of
a false-negative result for ischemic heart disease (dashed arrow) is thought to be low on the basis of the clinical presentation. Therefore, in such cases, a tentative
diagnosis of “true” cardiac syndrome X can here be made; DS ¼ diameter stenosis.
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461When both epicardial coronary spasm and microvascular
endothelial dysfunction can be excluded with the acetyl-
choline test, the presence of an endothelium-independent
dysfunction should be investigated with the adenosine test
(considered positive when CFR <2.5) (52).
If, in a patient with typical angina and robust suspicion of
myocardial ischemia documented with a noninvasive stress
test, neither the acetylcholine test nor the adenosine test
reveals any abnormal coronary dysfunction, then a “true”
cardiac syndrome Xdpotential myocardial ischemia due to
unknown and/or undetectable causesdcan be diagnosedbecause the probability of a false positive result for the
presence of IHD is deemed to be low. Parallel to this group,
one should also, however, list subjects with false-negative
test results for microvascular angina, such as patients
showing a normal FFR, a normal CFR, and an increased
IMR, in a condition that Echavarria-Pinto et al. (43)
recently classiﬁed as “suspected initial microvascular dys-
function.” The clinical signiﬁcance of this condition is
currently unknown but worth exploring, provided that such a
rigorous deﬁnition is applied. The clinical reality may clearly
still leave uncertainties of classiﬁcation, as highlighted in
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462Figure 2, when the presence of typical angina and/or the
objective diagnosis of ischemia as entry criteria in the algo-
rithm are themselves uncertain.
Conclusions
The failure to detect ﬁxed obstructive CAD in patients with
angina and signs of myocardial ischemia is a frequent clinical
scenario that can be due to different mechanisms. Because of
various prognostic and therapeutic implications, a correct
diagnosis of the underlying pathophysiology is warranted
and should be actively pursued. The intracoronary acetyl-
choline test allows at the same time the assessment of a
possible epicardial vasospasm and endothelium-dependent
microvascular dysfunction. Similarly, the use of a pressure
wire with the adenosine test may evaluate both the func-
tional signiﬁcance of a coronary lesion and endothelium-
independent microvascular dysfunction. A functional
assessment of both the epicardial coronary arteries and the
coronary microcirculation is strongly recommended to
identify patients at higher risk of coronary events and to
guide therapeutic strategies and should be much more widely
implemented.
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